A $5 Billion Blockbuster Emerges? JPMorgan Maintains "Neutral" Rating on Amgen (AMGN.US): A Good Drug Doesn't Equal a Good Entry Point

Zhitong Finance APP has learned that JPMorgan's latest research report states that Amgen (AMGN.US) last weekend at the ESMO conference announced Imdelltra first-line maintenance treatment data "impressive", which may support the drug's advancement into earlier treatment lines, making it a potential blockbuster product with $5 billion in peak sales. However, the bank still maintains a "Neutral" rating with a target price of $350, below the current stock price of about $439.